There are currently 120 active clinical trials seeking participants for Glioblastoma research studies. The states with the highest number of trials for Autism participants are California, Ohio, New York and Pennsylvania.
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors
NCT05917145
Recruiting
The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Glioblastoma
Register for Updates
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
NCT04574856
Recruiting
This study will investigate whether or not intensified radiation therapy adapted during the radiation treatment course to high-risk, treatment-resistant tumor regions will improve overall survival in patients with newly diagnosed glioblastoma (GBM) compared to conventional chemoradiotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Glioblastoma
Register for Updates
Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
NCT04922723
Recruiting
TMZ is a standard therapy for GBM. The study will demonstrate that Daratumumab can collaborate with TMZ to enhance the cytotoxicity against GBM cells. Collectively, the preclinical data along with existing in vivo studies by others provides the rationale for therapeutic targeting of CD38 in GBM and its microenvironment. Daratumumab is commercially available, is safe and well tolerated when combined with alkylating chemotherapy, radiation therapy and has attained therapeutic CSF levels. Thus, the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/10/2024
Locations: West Virginia University Cancer Institute Mary Babb Randolph Cancer Center, Morgantown, West Virginia
Conditions: Glioblastoma
Register for Updates
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and s... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
01/09/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +263 locations
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
NCT04869449
Recruiting
This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Ketoconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/06/2024
Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania
Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult
Register for Updates
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
NCT04825275
Recruiting
This research is being done to find out if the study drug (posaconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Posaconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/06/2024
Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania
Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult
Register for Updates
Tofacitinib in Recurrent GBM Patients
NCT05326464
Recruiting
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Glioblastoma
Register for Updates
Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
NCT04822688
Recruiting
This study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors. Studying samples of blood and tissue from patients with glioblastoma or other solid tumor in the laboratory may help doctors understand brain tumors and better inform future treatments.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Glioblastoma, Malignant Solid Neoplasm
Register for Updates
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
NCT05106296
Recruiting
Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) with indoximod (IDO-inhibitor) during chemotherapy will synergistically enhance anti-tumor immune responses, leading to improvement in clinical response with manageable overlapping toxicity. GCC2020 is... Read More
Gender:
All
Ages:
Between 12 years and 25 years
Trial Updated:
12/16/2023
Locations: Augusta University, Georgia Cancer Center, Augusta, Georgia
Conditions: Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
Register for Updates
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
NCT04049669
Recruiting
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism has been implicated in regulating immune responses in settings as diverse as infection, tissue/organ transplant, autoimmunity, and cancer. By inhibiting the IDO pathway, we hypothesize that indoximod will improve antitumor immune responses and thereby slow the growth of tumors. The central clinical... Read More
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
12/16/2023
Locations: Augusta University, Georgia Cancer Center, Augusta, Georgia +3 locations
Conditions: Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Register for Updates
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
NCT05686798
Recruiting
The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/14/2023
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme, GBM
Register for Updates
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
NCT04479696
Recruiting
This trial studies whether a customized video intervention can help to reduce anxiety in brain cancer patients undergoing radiation treatment and their caregivers. A customized neuro-imaging referenced symptom video that describes symptoms and side effects specific to the patients' tumor may result in an early and sustained reduction in anxiety and distress during and after radiation treatment, thereby improving quality of life.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/07/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
Register for Updates